JP2017508144A - 感情／気分障害のバイオマーカーとしてのソルチリンの使用 - Google Patents

感情／気分障害のバイオマーカーとしてのソルチリンの使用 Download PDF

Info

Publication number
JP2017508144A
JP2017508144A JP2016551166A JP2016551166A JP2017508144A JP 2017508144 A JP2017508144 A JP 2017508144A JP 2016551166 A JP2016551166 A JP 2016551166A JP 2016551166 A JP2016551166 A JP 2016551166A JP 2017508144 A JP2017508144 A JP 2017508144A
Authority
JP
Japan
Prior art keywords
sortilin
subject
bipolar disorder
sample
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508144A5 (enExample
Inventor
ジェプセン，ジェスパー，ルンドヘデ
ニクジャー，アンダース
モース，ニールズ，ピーター，オレ
ピーターセン，クロース，ムンク
オスターガード，ソレン，ダイネセン
グレラプ，サイモン
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2017508144A publication Critical patent/JP2017508144A/ja
Publication of JP2017508144A5 publication Critical patent/JP2017508144A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016551166A 2014-02-12 2015-02-06 感情／気分障害のバイオマーカーとしてのソルチリンの使用 Pending JP2017508144A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400075 2014-02-12
DKPA201400075 2014-02-12
PCT/EP2015/052506 WO2015121166A1 (en) 2014-02-12 2015-02-06 Use of sortilin as biomarker for affective/mood disorders

Publications (2)

Publication Number Publication Date
JP2017508144A true JP2017508144A (ja) 2017-03-23
JP2017508144A5 JP2017508144A5 (enExample) 2018-03-22

Family

ID=52462923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551166A Pending JP2017508144A (ja) 2014-02-12 2015-02-06 感情／気分障害のバイオマーカーとしてのソルチリンの使用

Country Status (6)

Country Link
US (1) US20160349276A1 (enExample)
EP (1) EP3105594A1 (enExample)
JP (1) JP2017508144A (enExample)
CN (1) CN105980858A (enExample)
HK (1) HK1232289A1 (enExample)
WO (1) WO2015121166A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
CN111351945B (zh) * 2020-03-18 2021-04-23 东南大学 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085555A2 (en) * 2010-12-20 2012-06-28 Cambridge Enterprise Limited Biomarkers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3165537A1 (en) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
GB0903417D0 (en) * 2009-02-27 2009-04-08 Cambridge Entpr Ltd Biomarkers
GB0922240D0 (en) * 2009-12-21 2010-02-03 Cambridge Entpr Ltd Biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085555A2 (en) * 2010-12-20 2012-06-28 Cambridge Enterprise Limited Biomarkers

Also Published As

Publication number Publication date
WO2015121166A1 (en) 2015-08-20
US20160349276A1 (en) 2016-12-01
HK1232289A1 (zh) 2018-01-05
CN105980858A (zh) 2016-09-28
EP3105594A1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
Käck et al. Molecular allergy diagnostics refine characterization of children sensitized to dog dander
O’Bryant et al. A blood-based algorithm for the detection of Alzheimer’s disease
US20160349276A1 (en) Use of Sortilin as Biomarker for Affective/Mood Disorders
Pengo et al. Antibody profiles for the diagnosis of antiphospholipid syndrome
US20200319207A1 (en) Treating schizophrenia based on a panel of biomarkers
Ma et al. Development of a Novel Urine Alzheimer‐Associated Neuronal Thread Protein ELISA Kit and Its Potential Use in the Diagnosis of Alzheimer's Disease
Bartosik‐Psujek et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
CN106537146A (zh) 生物标志
JP2007517188A (ja) 発作性脳発射を評価するための免疫吸着血液検査
EP2310858B1 (en) Therapeutic and diagnostic methods for alzheimer's disease
US20210349094A1 (en) Detection of autoreactive fecal immunoglobulin a (iga) for diagnosis of lupus
Hong et al. Serum ceramide concentrations are associated with depression in patients after ischemic stroke-A two-center case-controlled study
Reumiller et al. Gender-related increase of tropomyosin-1 abundance in platelets of Alzheimer's disease and mild cognitive impairment patients
Giannoccaro et al. Searching for serum antibodies to neuronal proteins in patients with myalgic encephalopathy/chronic fatigue syndrome
Gustaw-Rothenberg et al. Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer’s disease: A population-based study
Leisgang Osse et al. The common Alzheimer's disease research ontology (CADRO) for biomarker categorization
JP7808340B2 (ja) 軽度認知障害検査
WO2015019979A1 (ja) 統合失調症に関するバイオマーカー
JP5518836B2 (ja) 肺動脈高血圧を診断するための方法
Rietveld et al. Anti–cytosolic 5′‐nucleotidase 1A autoantibodies are absent in juvenile dermatomyositis
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
Rissardo et al. A biophysical framework for neurodegeneration: prioritizing protein homeostasis over aggregate toxicity
JP2005539228A (ja) 軽度の認知障害を示すアルツハイマー患者特有の診断方法
JP5991666B2 (ja) アルツハイマー病を検出する方法及びキット
JP2005513480A (ja) トロンボスポンジンを使用する痴呆の診断および治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190903